title: Successful bortezomib-based treatment in POEMS syndrome.
authors: Xiaowen
authors: X
authors: Tang
authors: Xiaolan
authors: X
authors: Shi
authors: Aining
authors: A
authors: Sun
authors: Huiying
authors: H
authors: Qiu
authors: Bin
authors: B
authors: Gu
authors: Huifen
authors: H
authors: Zhou
authors: Shengli
authors: S
authors: Xue
authors: Yuejun
authors: Y
authors: Liu
authors: Changgeng
authors: C
authors: Ruan
authors: Depei
authors: D
authors: Wu
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003864:Depression, Chemical; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D016878:POEMS Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D010950:Plasma Cells / Q000187:drug effects / Q000378:metabolism; D011241:Prednisone / Q000008:administration & dosage; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D012074:Remission Induction; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000378:metabolism; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D020533:Angiogenesis Inhibitors; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D003561:Cytarabine; D014750:Vincristine; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D011241:Prednisone